To include your compound in the COVID-19 Resource Center, submit it here.
A double-blind, U.S. Phase IIb trial in 189 patients with primary axillary hyperhidrosis showed that BBI-4000 met
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury